At the in-Cosmetics Global trade show, to be held in Paris from April 16 to 18, 2024, the Solabia group is unveiling its new ingredient for sensitive skin prone to atopy. Serenibiome is a patented double active based on flocculosin. This innovative glycolipid is obtained by biofermentation of Pseudozyma flocculosa and was inspired by this epiphytic fungus and the holobiont concept.
Pseudozyma flocculosa is an epiphytic fungus that acts as a biocontrol agent by maintaining a healthy ecological niche for its host plant. Pseudozyma flocculosa has been identified on plant leaves infected by downy mildew, and is known to prevent the colonization of phytopathogens by releasing a specific extracellular glycolipid with powerful properties: flocculosin. Serenibiome's activity on an unbalanced microbiome and weakened skin is bioinspired by Pseudozyma flocculosa and its interactions with its plant host. Thanks to this powerful glycolipid, Serenibiome protects the skin holobiont.
A glycolipid from biotechnology
Backed by 30 years of expertise in biotechnology, the Solabia group has succeeded in developing an industrial process that mimics the natural production of flocculosin by Pseudozyma flocculosa. Serenibiome is the culmination of over eight years of R&D to develop an optimized bioguided fermentation process that induces the metabolic pathway of the fungus.
This white biotechnology process meets high CSR standards thanks to water and energy management, a low-temperature process and low carbon emissions, and results in high-purity flocculosin, according to Sloabia.
Serenibiome is a 100 % natural active ingredient, Cosmos-approved, preservative-free, eco-designed and easily biodegradable, suitable for sensitive skin prone to atopy.
Proven effectiveness
"Applied to skin health, Serenibiome has demonstrated exceptional and unmatched in vitro efficacy in bioselectively targeting the growth of Staphylococcus aureus without impacting the commensal population of Staphylococcus epidermidis "says Solabia.
S. aureus is the prevalent opportunistic bacterium implicated in the dysbiosis of the microbiome in atopy-prone skin, and recent studies have also shown its involvement in neurogenic inflammation, inducing itching and scratching by stimulating pruriceptors in sensory neurons. According to the company, preclinical studies have demonstrated the efficacy of Serenibiome on the drivers of the itch-scratch vicious circle, and this efficacy has been clinically confirmed by a metagenomic study with a correlated reduction in Scorad.
"Serenibiome significantly improves the skin condition of children with mild to moderate atopic dermatitis after 28 days, calms neurogenic inflammation, helps limit pro-inflammatory signaling, enhances wellness neurotransmitters and supports the skin barrier."adds Solabia.
Photo: Iqbal Nuril Anwar / Pixabay
